logo
States can cut off Medicaid funding to Planned Parenthood, the Supreme Court rules

States can cut off Medicaid funding to Planned Parenthood, the Supreme Court rules

Independent4 hours ago

The Supreme Court allowed states to cut off Medicaid money to Planned Parenthood in a ruling handed down Thursday amid a wider Republican-backed push to defund the country's biggest abortion provider.
The case centers on funding for other health care services Planned Parenthood provides in South Carolina, but the ruling could have broader implications for Medicaid patients.
Public health care money generally can't be used to pay for abortions. Medicaid patients go to Planned Parenthood for things like contraception, cancer screenings and pregnancy testing, in part because it can be tough to find a doctor who takes the publicly funded insurance, the organization has said.
South Carolina's Republican governor says no taxpayer money should go the organization. The budget bill backed by President Donald Trump in Congress would also cut Medicaid funding to Planned Parenthood. That could force the closure of about 200 centers, most of them in states where abortion is legal, the organization has said.
Gov. Henry McMaster first moved to cut off Medicaid funding to Planned Parenthood in 2018 but was blocked in court after a lawsuit from a patient named Julie Edwards. Edwards wanted to keep going there for birth control because her diabetes makes pregnancy potentially dangerous, so she sued over a provision in Medicaid law that allows patients to choose their own qualified provider.
South Carolina, though, argued that patients shouldn't be able to file those lawsuits. The state pointed to lower courts that have been swayed by similar arguments and allowed states such as Texas to block Medicaid funding from Planned Parenthood.
Public health groups like the American Cancer Society, by contrast, said in court papers that lawsuits are the only real way that Medicaid patients have been able to enforce their right to choose their own doctor. Losing that right would reduce access to health care for people on the program, which is estimated to include one-quarter of everyone in the country. Rural areas could be especially affected, advocates said in court papers.
In South Carolina, $90,000 in Medicaid funding goes to Planned Parenthood every year, a tiny fraction of the state's total Medicaid spending. The state banned abortion at about six weeks' gestation after the high court overturned it as a nationwide right in 2022.
___

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump rejected invitation to Bezos wedding
Trump rejected invitation to Bezos wedding

Telegraph

time31 minutes ago

  • Telegraph

Trump rejected invitation to Bezos wedding

Donald Trump rejected an invitation to Jeff Bezos's star-studded Venetian wedding. Mr Bezos, the tech billionaire, was reportedly trying to cosy up to the US president, in what could be seen as an attempt to fill the position of 'First Buddy' vacated by Elon Musk. The Wall Street Journal (WSJ) reported that the 61 year-old, who is preparing for his lavish three-day wedding in Venice, had spoken twice to Mr Trump in the last few weeks. As part of his charm offensive, Mr Bezos extended an invitation to his upcoming nuptials with Lauren Sanchez, the journalist. White House officials confirmed to the WSJ that the invitation had been offered. Mr Trump was not expected to attend the Venice ceremony owing to scheduling conflicts, however. Mr Trump's daughter Ivanka, a friend of Ms Sanchez' is expected to attend, along with her husband, Jared Kushner. Donald Jr, the president's eldest son, is also going. In 2019, Mr Trump mocked Mr Bezos as 'Jeff Bozo' in a dig at the Washington Post, which the billionaire owned. However, the newspaper did not support Kamala Harris in last year's presidential election, breaking a liberal tradition going back decades. In February, the Post refused to run an advert attacking the administration that asked whether Donald Trump or Elon Musk was running the country. Earlier this year, Mr Bezos abandoned plans to display how much Mr Trump's proposed tariffs were costing Amazon customers on each transaction following a direct appeal from the president. Mr Bezos, the founder of Amazon and one of the world's richest men, appears to be trying to exploit Mr Trump's spectacular falling out with Mr Musk, which started at the end of last month. Dave Limp, chief executive of Mr Bezos's space company Blue Origin, has also held talks with Susie Wiles, the White House Chief of Staff, the WSJ reported. There are powerful business reasons for Bezos's approach, notably the possibility of government contracts for Blue Origin. Until now, Elon Musk's SpaceX has dominated the market, spectacularly outstripping Blue Origin in the race to become Nasa's main contractor since the US stopped using the Russians to ferry missions to the International Space Station.

Elon Musk's right-hand man ‘quits Tesla'
Elon Musk's right-hand man ‘quits Tesla'

Telegraph

time31 minutes ago

  • Telegraph

Elon Musk's right-hand man ‘quits Tesla'

One of Elon Musk's closest allies at Tesla has left the company amid a deepening crisis at the electric carmaker. Omead Afshar, a senior executive who has been described as Mr Musk's 'fixer', has stepped down from his role at the company, according to Bloomberg. Mr Afshar joined Mr Musk's company in 2017 and rose to run Tesla's operations in North America and Europe. It was not immediately clear why Mr Afshar had left Tesla. He has boasted of his close relationship with Mr Musk, including their intense work schedule during the troubled production of Tesla's Model 3 Sedan. 'I was with Elon nearly every single day during Model 3 Hell. This included Thanksgiving, Christmas, New Year's Eve, his birthday and nearly missing his brother's wedding,' Mr Afshar recently wrote on X, Mr Musk's social media site. He also oversaw the building of Tesla's factory in Austin, Texas, which is now the company's headquarters. Mr Afshar's departure follows the exit this month of Milan Kovac, Tesla's head of engineering for the company's Optimus robot program. Mr Kovac said he wanted to spend more time with family. They are leaving as Tesla battles a sales slump amid a politically motivated backlash – Mr Musk has been a key supporter of Donald Trump – and fierce competition from Chinese rivals. Chinese giant BYD overtook Tesla to become the world's biggest electric vehicle (EV) manufacturer this year and Skoda sold more EVs than Mr Musk's company in Europe last month. Net income at the company crashed by 71pc to $409m (£297m) in the first three months of the year in what was its least profitable quarter since 2020. Shares have dropped by more than 25pc in the last six months. Mr Musk publicly stepped back from his role in Mr Trump's administration in May following the backlash against Tesla, but stressed that the work of his so-called department of government efficiency (Doge) would continue. But he later lashed out at the president over Mr Trump's spending bill and its implications for America's debt burden. In a sign of the intensity of the backlash against Mr Musk over his association with Mr Trump, a group of French drivers sued the company this month, claiming the billionaire was turning their vehicles into 'extreme Right' symbols.

RFK Jr's federal vaccine panel votes against chemical in flu vaccines
RFK Jr's federal vaccine panel votes against chemical in flu vaccines

The Guardian

time32 minutes ago

  • The Guardian

RFK Jr's federal vaccine panel votes against chemical in flu vaccines

A critical federal vaccine panel has recommended against seasonal influenza vaccines containing a specific preservative – a change likely to send shock through the global medical and scientific community and possibly impact future vaccine availability. The panel was unilaterally re-made by health secretary Robert F Kennedy Jr, a vaccine skeptic who has urged against the use of thimerosal despite a lack of evidence of real-world harm. Across three votes, members voted in favor of restricting thimerosal in seasonal influenza vaccines across all age groups – with five in favor of the restriction, one abstention and one vote against. 'The risk from influenza is so much greater than the nonexistent – as far as we know – risk from thimerosal,' said Dr Cody Meissner, a panel member and professor of pediatrics at Dartmouth's Geisel School of Medicine who was the lone 'no' vote. 'I would hate for a person not to receive the influenza vaccine because the only availability preparation contains thimerosal – I find that very hard to justify.' The panel, formally called the Advisory Committee for Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), is a critical link in the vaccine distribution pipeline – informing health insurers and clinicians alike about which vaccines to give patients. Kennedy fired all 17 former members of the panel in June, citing conflicts of interest, and appointed eight new members, all of whom are ideological allies of the secretary. None of the new members have published written conflict of interest disclosures or been added to a Trump administration-developed conflict of interest tracker for ACIP members, as of Thursday morning. 'There is a very big difference between what was shared at the meeting versus what is reality,' said Dr Sean O'Leary, chair of the American Academy of Pediatrics Committee on Infectious Diseases. 'The science on thimerosal is settled, and the rhetoric being used to suggest otherwise is misleading and harmful.' Rather than vote on an agenda that had once included seasonal recommendations for Covid-19 and the vaccine against human papilloma virus (HPV), ACIP added the controversial focus of thimerosal in vaccines. The panel affirmed that the influenza vaccine is recommended for Americans older than six months. Although multiple studies have found no real-world harm, the preservative has been a talking point of anti-vaccine advocates for decades. Multiple representatives of physicians associations urged the panel to reject the recommendation against thimerosal in the meeting. Thimerosal is used in about 5% of multidose seasonal influenza vials, and is known to be more cost effective than single-dose formulations. It is unclear how the vote will impact flu vaccine availability before the upcoming flu season, particularly for clinics that rely on such formulations. Thimerosal has been used as a preservative in vaccines since before the second world war. In the early 2000s, thimerosal was removed from all routine pediatric and most adult vaccines as a precautionary measure – a decision that was criticized by experts who argued it sent mixed messages about a preservative that had not been found to cause harm. The issue has since been considered settled by mainstream medicine. Thimerosal is an ethylmercury-based preservative. Ethylmercury is different from the kind of mercury found in seafood, called methylmercury. Ethylmercury has a much shorter half-life in the blood and brain, about seven days and 30 days respectively, compared to methylmercury, which has an approximately 44-58 day half-life and accumulates in the brain. The amount of ethylmercury contained in a flu vaccine (25 micrograms) is about half of that contained in a 3-ounce serving of canned tuna fish (40 micrograms). Repeated, large studies conducted across several countries have found no association between thimerosal and neurological effects. A presentation from CDC career scientists that was initially expected to go through some of this substantial data was removed before the panel reconvened on Thursday. In response to a question about the slapped down presentation, ACIP member Dr Robert Malone, a well-known anti-vaccine activist, said: 'That article was not authorized by the office of the secretary and was removed.' The panel instead heard a presentation from Lyn Redwood, a nurse practitioner who founded the World Mercury Project, the predecessor to Kennedy's anti-vaccine advocacy group Children's Health Defense. Prior to the meeting, her presentation was found to include a reference to a study that appeared to be made up. 'This is an old issue that has been addressed in the past and there are many issues we could discuss,' said Meissner. Responding to criticism of Redwood's presentation, ACIP chair Dr Martin Kulldorff, a former Harvard professor who was fired for refusing the Covid-19 vaccine, said: 'It's inappropriate to dismiss a presentation just because the person does not have a PhD or MD.' The decision from ACIP could have global implications, because vaccines used around the world rely on thimerosal as a preservative in multidose vials, which are less expensive. 'I know ACIP is focused on the US, but recommendations that the ACIP makes are followed among many countries around the world,' said Meissner. 'Removing thimerosal from all vaccines used in other countries, for example, is going to reduce access to these vaccines, it will increase costs, and I think it's important to note that no study has ever indicated any harm from thimerosal.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store